CO1 The Health Outcome Analysis of Sintilimab for the First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: According to the Eq-5D-5L
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.082
https://www.valueinhealthjournal.com/article/S1098-3015(22)02286-0/fulltext
Title :
CO1 The Health Outcome Analysis of Sintilimab for the First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: According to the Eq-5D-5L
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02286-0&doi=10.1016/j.jval.2022.09.082
First page :
Section Title :
Open access? :
No
Section Order :
10362